Content area

|
|

Statens investering i kliniske forsøg

Forfatter(e)
Sofie Louise Rygård, Maj-Brit Nørregaard Kjær & Anders Perner Intensiv Terapiklinik, Rigshospitalet Ugeskr Læger 2018;180:V09170645
Reference: 
Ugeskr Læger 2018;180:V09170645
Blad nummer: 
Sidetal: 
2-4
Danish public research investments in clinical trials
Clinical trials are important to ensure that patients and society benefit from healthcare interventions. Among the Danish public research investments in medical sciences the main part of funding is given to preclinical and translational research, and less than ten per cent is given to clinical trials. This imbalance may have negative consequences for patients and society, because public investment in clinical trials is likely to ensure broader availability of tested interventions independent of diseases, patient groups, caregivers and clinical settings.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af David McWhan | 27/11
4 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Jan Nielsen | 23/11
1 Kommentar
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar
af Niels Holmark Andersen | 20/11
1 Kommentar